

Prostatype Genomics receive commitments covering additionally 20 percent of the ongoing TO 4 exercise

NOT FOR RELEASE, PUBLICATION, OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, THE UNITED KINGDOM, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS, OR ANY OTHER JURISDICTION WHERE THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE MEASURES OTHER THAN THOSE REQUIRED UNDER SWEDISH LAW. SEE THE SECTION "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.

Prostatype Genomics AB ("Prostatype Genomics" or "Company") announces that the Company has received guarantee commitments in the ongoing exercise of warrants of series TO 4 ("TO 4"). The guarantee commitments of approximately SEK 2.0 million have been received from two external investors, and they cover approximately 20 percent of the number of outstanding warrants.

Prostatype Genomics has entered into agreements for guarantee commitments with external investors amounting to approximately SEK 2.0 million, corresponding to approximately 20 percent of the proceeds from the TO 4 exercise up to 80 percent of the maximum subscription amount.

Furthermore, the Company announces adjustments to the indicated commitments from existing shareholders communicated via the press release on November 26, 2024. The adjustment entails that a declaration of intent to exercise warrants corresponding to 5 percent of the total number of warrants has been amended into a top guarantee (from 100 percent and downwards). The reason for the adjustment is that the subscriber has been offered to receive warrants from another shareholder, but this is no longer possible due to administrative issues in the process of transferring the TO 4 warrants. Additionally, a previously communicated declaration of intent to exercise warrants has been raised with approximately 3 percent.

If the guarantee commitments are activated, this will be carried out through a directed issue at a subscription price equivalent to the exercise price for TO 4, which is SEK 5.96 per share. For the provided guarantee commitments, the guarantors will receive either a cash compensation of 8 percent of the guaranteed amount or 10 percent in the form of additional shares. The guarantee compensation has been determined through negotiations between the Company and the guarantors at arm's length and with the assistance of financial advisors. Guarantee commitments have not been secured through pre-transactions, bank guarantees, or similar measures.

Following the adjustments, the declarations of intent to exercise warrants amount to approximately 35 percent of the total amount of TO 4. Guarantee commitments, as described above, ensure that the Company will receive additional proceeds corresponding to approximately 25 percent of the total amount of TO 4.

Complete terms and instructions for warrants of series TO 4, as well as an information folder containing summary information about the warrant exercise, are available on Prostatype Genomics' (www.prostatypegenomics.com) and Nordic Issuing AB's (www.nordic-issuing.se) respective websites during the exercise period.



Important dates

- 5 December 2024: Final day of trading with TO 4
- 9 December 2024: Exercise period ends.
- 10 December 2024: Preliminary date for announcement of outcome of the exercise.
- 20 December 2024: Preliminary date for conversion from interim shares to ordinary shares.

Complete terms and instructions for warrants of series TO 4 are available on the Company's website (www.prostatypegenomics.com). An information folder containing summary information about the warrant exercise is available on Prostatype's and Nordic Issuing AB's (www.nordic-issuing.se) respective websites during the exercise period.

Advisors

In connection with the warrant exercise, Prostatype has engaged Gemstone Capital A/S as financial advisor, Advokatfirman Lindahl KB as legal advisor and Nordic Issuing AB as issuing agent.

For more information, please contact:

Fredrik Rickman, VD Tel: +46 (0)73-049 77 01

E-mail: fredrik.rickman@prostatypegenomics.com


About Prostatype

Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision support tool to answer the question of radical treatment or no radical treatment of prostate cancer. The test was developed by a leading research group at Karolinska Institutet and is provided by Prostatype Genomics AB.

Important Information

This press release does not constitute an offer to acquire, subscribe for, or otherwise trade in shares, warrants, unit rights, BTUs, or other securities in Prostatype Genomics AB. Investors should not subscribe for or acquire any securities other than on the basis of the information in the prospectus published prior to the commencement of the subscription period in the Rights Issue. No action has been or will be taken to allow a public offering in any jurisdictions other than Sweden.

This press release may not be released, published, or distributed, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, the United Kingdom, South Africa, South Korea, Russia, Belarus, or any other jurisdiction where the distribution of this press release would be unlawful. This press release does not constitute an offer to sell new shares, warrants, subscription rights, BTUs, or other securities to any person in a jurisdiction where such an offer would be unlawful or would require prospectuses, additional registration, or other measures beyond those required by Swedish law. The prospectus and other documents related to the Rights Issue may not be distributed in or into any country where such distribution or the Rights Issue requires actions as mentioned above or where it would conflict with the regulations of such country. Any actions in violation of these instructions may constitute a breach of applicable securities laws.





No shares, warrants, unit rights, BTUs, or other securities have been or will be registered under the United States Securities Act of 1933, as amended (the "Securities Act"), or under the securities laws of any state or other jurisdiction of the United States, and may not be offered, subscribed for, exercised, pledged, sold, resold, allotted, delivered, or otherwise transferred, directly or indirectly, in or into the United States, except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of the relevant state or other jurisdiction of the United States.

This press release may contain certain forward-looking statements reflecting the Company's current views on future events as well as financial and operational developments. Words such as "intends," "assesses," "expects," "may," "plans," "believes," "estimates," and other expressions indicating or predicting future developments or trends and that are not based on historical facts constitute forward-looking statements. Forward-looking statements are, by nature, associated with both known and unknown risks and uncertainties, as they depend on future events and circumstances. Forward-looking statements do not constitute a guarantee of future results or developments, and actual outcomes may differ materially from what is expressed in the forward-looking statements. Neither the Company nor any other party undertakes to review, update, confirm, or publicly announce any revisions of any forward-looking statements to reflect events that occur or circumstances that arise with regard to the content of this press release, unless required by law or the Nasdaq First North Growth Market's regulations.

This information is information that Prostatype Genomics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-12-03 15:40 CET.